RxDoctor Payments Data

George Ipe, MD

Internal Medicine · Dallas, TXNPI 1528360021

Payments from drug & device makers

$2,446in general payments, 2019–2025

Across 142 payments — averaging $17.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$589
  • GSK$268
  • Astellas Pharma US Inc$219
  • Amgen$210
  • Johnson & Johnson$183
  • AbbVie$142
  • plus $836 from 18 others

What the payments were for

  • Food & beverage$2,446100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,446 in reported general payments places this provider in the 80th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$131,464
Medicare patients
216
Services billed
1,768

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban24$25,175
XareltoRivaroxaban29$20,459
OzempicSemaglutide21$20,392
RybelsusSemaglutide12$11,689
Atorvastatin Calcium561$4,978
Breo ElliptaFluticasone/Vilanterol11$4,188
SymbicortBudesonide/Formoterol Fumarate11$2,573
Losartan Potassium287$2,534
SynthroidLevothyroxine Sodium21$1,894
Nifedipine ErNifedipine77$1,748
Omeprazole131$1,691
Amlodipine Besylate321$1,588
Pravastatin Sodium160$1,575
Levothyroxine Sodium165$1,566
Ezetimibe80$1,451

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$589$32,08133 claims
PfizerEliquis$108$25,17524 claims
Johnson & JohnsonXarelto$183$20,45929 claims
GSKBreo Ellipta$268$4,18811 claims
AstraZenecaSymbicort$113$2,57311 claims
AbbVieSynthroid$142$1,89421 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →